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Integration of Peripheral and Glandular Regulation 
of Triiodothyronine Production by Thyrotropin in 
Untreated and Thyroxine-Treated Subjects
control of T3 homeostasis has been mostly 
viewed as auto-regulated and operating inde-
pendently of the central hypothalamic pituitary 
regulation [4, 8, 9]. However, we have recently 
shown that the healthy equilibria between thy-
roid hormones and pituitary thyrotropin (TSH) 
appear not to be fixed, but adapt in different 
ways to various conditions including levothyrox-
ine (L-T4) treatment [10].
We hypothesised that the peripheral and central 
pathways may be coordinated and, in particular, 
a functional TSH-deiodinase feed-forward motif 
may be operative in humans in vivo that could 
play a major role in both fine-tuning T3 homeo-
stasis and maintaining optimum adaptive circu-
latory FT3 levels over a wide variation in thyroid 
production.
To examine the hypothesis, we used data 
obtained from a large prospective study to assess 
the contributions of thyroid secretory capacity 
and deiodinase activity to T3 homeostasis [10]. 
The findings confirm the hypothesis and suggest 
that circulatory T3 concentrations are jointly 
Introduction
▼
Thyroid hormone homeostasis is tightly regu-
lated by 2 major processes, hypothalamic pitui-
tary thyroid feedback controlling thyroid 
hormone production and thyroxine (T4)-triiodo-
thyronine (T3) conversion supplying the majority 
of the latter biologically active hormone. The 
conversion mechanism involves 3 types of deio-
dinases termed deiodinase 1 (D1), 2 (D2), and 3 
(D3), which differ in both their functionalities 
and their expression depending on organ, devel-
opmental stage and thyroid function [1, 2]. Deio-
dination of T4 is assumed to account for 
approximately 80 % of the T3 production in 
humans [3, 4]. However, challenging the essential 
physiological role that has been ascribed to this 
mechanism, knock-out mice deficient in either 1 
or even all 3 deiodinases showed little pheno-
typic alterations, maintaining sufficient, if not 
optimum, thyroid hormone homeostasis for the 
continued functioning of vital developmental 
and metabolic processes [5–7]. The peripheral 
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Abstract
▼
The objective of the study was to evaluate the 
roles of central and peripheral T3 regulation. In a 
prospective study involving 1 796 patients, the 
equilibria between FT3 and TSH were compared 
in untreated and L-T4-treated patients with vary-
ing functional states, residual thyroid secretory 
capacities and magnitudes of TSH stimulation. T3 
concentrations were stable over wide variations 
in TSH levels (from 0.2 to 7 mU/l) and endoge-
nous T4 production in untreated patients, but 
unbalanced in L-T4-treated athyreotic patients 
where T3 correlated with exogenous T4 supply. 
T3 stability was related to TSH-stimulated deio-
dinase activity by clinical observation, as pre-
dicted by theoretical modelling. Deiodinase 
activity in treated patients was reduced due to 
both diminished responsiveness to TSH and lack 
of thyroidal capacity. Deiodinase activity was 
increased in high thyroid volume, compared to 
lower volumes in euthyroid patients ( < 5 ml, 
p < 0.001). While deiodinase differed between 
euthyroid and subclinically hypothyroid patients 
in high volume, 26.7 nmol/s (23.6, 29.2), n = 214 
vs. 28.9 nmol/s (26.7, 31.5), n = 20, p = 0.02, it was 
equivalent between the 2 functional groups in 
low volume, 23.3 nmol/s (21.3, 26.1), n = 117 vs. 
24.6 nmol/s (22.2, 27.5), n = 38, p = 0.22. These 
findings suggest that the thyroid gland and 
peripheral tissues are integrated in the physio-
logical process of T3 homeostasis in humans via a 
feed-forward TSH motif, which coordinates 
peripheral and central regulatory mechanisms. 
Regulatory and capacity deficiencies collectively 
impair T3 homeostasis in L-T4-treated patients.
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regulated by central and peripheral pathways, in order to main-
tain the hormone in a tight concentration range over a wide 
variation in endogenous T4 supply. The situation sharply differs 
in L-T4-treated athyreotic patients where the normal homeo-
static mechanisms are compromised.
Materials and Methods
▼
Study design and objective
A prospective open observational study (ClinicalTrials.gov, Study 
ID IIFHT-161013, NCT01969552) was conducted at the Depart-
ment of Nuclear Medicine at Klinikum Luedenscheid, Germany 
between July 2013 and February 2014, and approved by the Eth-
ics Committee of the University of Muenster, Germany. All par-
ticipants were adults, free of severe comorbidity and provided 
written informed consent.
The primary study outcome, the interrelation of thyroid param-
eters under various conditioning influences such as higher age, 
obesity, and L-T4 treatment has been reported [10]. The present 
analysis focuses on investigating additional homeostatic mecha-
nisms, particularly an integrating role of TSH stimulation, thy-
roid capacity and deiodinase activity on T3 homeostasis.
Patients
The study involved 1 796 consecutive patients, after excluding 
from analysis patients with hypothalamic/pituitary diseases 
(n = 5), pregnancy (n = 3), on antithyroid drugs (n = 99) or T3/T4 
combination therapy (n = 9). Hospitalisation of some patients 
(22 %) stemmed from German legal requirements that preclude 
ambulatory radioiodine application. L-T4 medication was with-
drawn from some before hospitalisation.
Diagnostic procedures included a detailed history supplemented 
by a standardised questionnaire documenting gender, age, 
height, weight, smoking habits (75 % answered), prior surgery or 
radioiodine treatment, medication (duration, brand, dosage, 
time of intake), physical examination, laboratory tests (FT3, FT4, 
TSH, and, if indicated, TPO-Ab or TSH-R Ab) and thyroid imaging.
Laboratory methods
TSH, FT3 and FT4 were measured with an automated direct 
chemoluminescence method (Advia Centaur XP, Siemens 
Healthcare Diagnostics, Erlangen, Germany). For TSH, the 3rd 
International Standard for TSH (WHO, IRP 81/565) was used, 
the range from 0.006 to 160.03 mU/l was linear, and CVs of 
inter-assay imprecision ranged from 0.9 % to 2.4 %. Labora-
tory-established and extensively evaluated reference inter-
vals were used, 0.4–4.0 mU/l for TSH, 10–23 pmol/l for FT4, 
and 3.1–6.8 pmol/l for FT3.
Thyroid peroxidase antibodies (TPO-Ab) were determined by a 
competitive chemoluminescence method (ADVIA Centaur XP, 
Siemens Healthcare Diagnostics, Erlangen, Germany, reference 
range < 60 U/ml) and TSH-receptor antibodies (TSH-R Ab) by a 
competitive ELISA (Euroimmun AG, Lübeck, Germany, reference 
range < 2 U/l).
Deiodinase activity and thyroid secretory capacity
We calculated the sum activity of peripheral deiodinases 
(termed deiodinase activity thereafter, nmol/s), from equilib-
rium levels of FT4, FT3 and estimated constant parameters for 
plasma protein binding, distribution and elimination with
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as previously described [11].
Deiodinase activity serves as a measure of conversion, similarly 
to the FT3-FT4 ratio, which is also given for comparison.
The maximum functional secretory capacity of the thyroid 
gland, amount of T4 released into the circulation per unit of time 
(pmol/s or nmol/d) (termed T4 output or supply), was estimated 
according to a previously published mathematical model of thy-
roid hormone homeostasis [11–13].
In the absence of a thyroid gland in L-T4-treated patients, we 
estimated the T4 supply from the daily hormone intake (T4 dose 
expressed in molar units), assuming a standard absorption rate 
of 70 %. The theoretical relationship between FT3 values and thy-
roid hormone output (GT) was simulated with the use of the 
application SimThyr 3.3 (developed by one of the authors and 
downloadable from sourceforge.net). The entire mathematical 
model including the parameters and equations used here have 
been made publicly available, validated in previous publications 
and were conceptualised in a recent review [11–13].
Thyroid ultrasound and scintigraphy
Thyroid volume was sonographically (10 MHz transducer) 
determined according to the ellipsoid formula. Reference values 
were  < 18 ml for females and  < 25 ml for males. A volume  < 1 ml 
was considered athyreotic. Larger nodules were further exam-
ined by scintigraphy.
Statistical methods
Descriptive data are reported as median plus interquartile range 
(IQR). Comparison of baseline characteristics was based on Wil-
coxon’s rank sum or chi square test in case of categorical varia-
bles. Multiple variables and influences were analysed by a 
generalised linear model (GLM). Non-linear relationships that 
existed over a wide range were approximated by locally weighted 
smooth regression, simpler relationships over restricted inter-
vals fitted by linear regression. Statistical analyses were per-
formed using Deducer (version 0.7-7) and the R statistical 
package (Mac version 3.1.0) [14, 15]. p-Values < 0.05 were con-
sidered significant.
Results
▼
Untreated subjects
Characteristics of patients are given in  ●▶  Table 1. In untreated 
subjects (n = 1 126), FT3 concentrations were maintained in a 
tight range over a wide span of TSH concentrations (from 
approximately 0.2 to 7 mU/l TSH) as reflected by a flat FT3-lnTSH 
gradient ( ●▶  Fig. 1). In contrast, FT4 and particularly deiodinase 
activity varied to a greater extent over the TSH range, made 
apparent when comparing the mean standardised parameters 
( ●▶  Fig. 1). T3 homeostasis was better preserved than FT4 levels, 
while deiodinase activity increased at both functional extremes, 
thereby contributing to both T3 excess in hyperthyroidism 
and T3 restoration in hypothyroidism in untreated patients 
( ●▶  Fig. 1).
When relating the estimated secretory capacity of the thyroid 
gland to circulating FT3 levels a similar pattern emerged, show-
ing that FT3 was maintained at stable level over a wide variation 
in endogenous T4 supply ( ●▶  Fig. 2a). The observed relationship 
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was strikingly different from what might be expected on theo-
retical grounds, and predicted by a theoretical model assuming 
peripheral autoregulation, that is, absence of a postulated 
T3-stabilising TSH-deiodinase interaction ( ●▶  Fig. 2b).
L-T4-treated patients
L-T4-treated patients showed lower median FT3 levels, com-
pared to untreated subjects ( ●▶  Table 1), and their T3 relationship 
was unbalanced. This followed virtually the same descending 
gradient as FT4 from lower to higher TSH levels, with a steep 
decline towards the hypothyroid end ( ●▶  Fig. 3a). FT3 levels were 
closely associated with both the daily weight-adjusted T4 dose 
( ●▶  Fig. 3b) and the estimated total exogenous T4 supply ( ●▶  Fig. 
3c) in a subgroup of athyreotic thyroid carcinoma patients that 
were non-hypothyroid on stable medication (n = 137,  ●▶  Table 1). 
For comparison, FT3 was stable and unrelated to similar changes 
in endogenous T4 supply in untreated controls ( ●▶  Fig. 3c).
In euthyroid L-T4-treated patients with low thyroid volume 
(< 5 ml, n = 117), deiodinase activity was lower, compared to the 
higher volume group ( ≥ 5 ml, n = 214), 23.3 nmol/s (21.3, 26.1) 
vs. 26.7 nmol/s (23.6, 29.2), p < 0.001. Deiodinase activity did not 
differ between euthyroid and subclinically hypothyroid subjects 
in the low volume group, 23.3 nmol/s (21.3, 26.1), n = 117 vs. 
24.6 nmol/s (22.2, 27.5), n = 38, p = 0.22, but did so at higher vol-
umes, 26.7 nmol/s (23.6, 29.2), n = 214 vs. 28.9 nmol/s (26.7, 
31.5), n = 20, p = 0.02 ( ●▶  Fig. 4). In the low volume group, 82 % of 
the patients had surgery, 68 % radioiodine treatment, and 8.5 % 
suffered from autoimmune thyroiditis. In a multivariable model, 
thyroid volume and thyroid state defined as either euthyroidism, 
subclinical hypothyroidism or hypothyroidism remained inde-
pendently influential on deiodinase activity (p < 0.001 for each 
parameter).
Discussion
▼
In the present study we have shown that maintenance of T3 
homeostasis is a preeminent goal in thyroid hormone metabo-
lism that apparently requires a coordinated interaction of cen-
tral and peripheral regulatory mechanisms. We present clinical 
and modelling evidence that the 2 processes are more closely 
interlocked than previously thought. Their intricate interrela-
tion contrasts with the prevailing view where T4 production is 
assumed to be subject to TSH control and T3 generation pre-
dominantly under peripheral “autoregulation” [4, 8, 9]. Con-
versely, we find TSH acts as a main integrator, technically 
feed-forward motif, that not only regulates T4 production by the 
thyroid gland, but also controls T3 conversion from T4 thereby 
fine-tuning and stabilising FT3 levels.
The present in vivo results expand on previous experimental 
findings showing that deiodinases respond sensitively to intra-
cellular cAMP concentrations, which, in turn, are modified by 
TSH [16–23]. Our observation that deiodinase activity is equally 
enhanced at the hypothyroid and hyperthyroid extreme may be 
explained in part by the same mechanisms, because, both TSH 
receptor stimulating antibodies in Graves’ disease and TSH 
receptor activating mutations in toxic adenomas are known, like 
TSH, to enhance intracellular cAMP levels [24, 25].
Table 1 Patient characteristics.
Parameter Untreated patients
n = 1126
L-T4-Treated patients
n = 670
L-T4-Treated athyreotic patients
n = 137
Gender (female) 75 % 78 % 69 %
Age (years) 53 (42, 67) 56 (45, 65)* 53 (47, 62)
BMI (kg/m2) 26.2 (23.5, 30.1) 27.4 (24.0, 31.1)** 28.4 (24.7, 33.6)** 
No thyroid diseasea 132 (12 %) 0 (0 %) 0 (0 %)
Euthyroid goitre or nodule 402 (36 %) 110 (16 %) 0 (0 %)
Hyperthyroid nodular disease 270 (24 %) 0 (0 %) 0 (0 %)
Hyperthyroid Graves’ disease 69 (6 %) 0 (0 %) 0 (0 %)
Autoimmune thyroiditis 146 (13 %) 110 (16 %) 0 (0 %)
Post intervention for benign disease 85 (8 %) 193 (30 %) 0 (0 %)
for thyroid carcinoma 19 (2 %) 252 (38 %) 137 (100 %)
Others 3 (0.3 %) 5 (0.4 %) 0 (0 %)
Intervention: surgery, radioiodine treatment 43 (4 %), 65 (6 %) 375 (57 %)**, 293 (45 %)** 137 (100 %)**, 134 (98 %)** 
L-T4 dose (μg/d) 0 100 (75, 125)** 150 (125, 175)** 
Weight-adjusted L-T4 dose (μg/kg BW) 0 1.37 (0.97, 1.70) 1.71 (1.52, 2.03)
Thyroid volume (ml) 16 (11, 25) 3 (0, 9)**  < 1** 
FT4 (pmol/l) 14.4 (13.2, 15.8) 17.0 (14.5, 19.6)** 20.9 (18.9, 23.2)** 
FT3 (pmol/l) 5.1 (4.7, 5.5) 4.7 (4.1, 5.2)** 5.1 (4.7, 5.7)
TSH (mU/l) 1.07 (0.46, 1.88) 1.08 (0.38, 3.04)* 0.12 (0.02, 0.69)** 
TPO-Ab (U/ml), n = 764 42 (33, 70) 59 (36, 1300)** –
TPO-Ab positive (%) 26 % 50 %
TSH-R Ab (U/l), n = 329 0.21 (0.2,1.0) 0.2 (0.2, 0.7) –
TSH-R Ab positive (%) 10 % 6 %
FT3- FT4 ratio (%) 36 (32, 39) 28 (24, 32)** 25 (22, 28)** 
Deiodinase activity (nmol/s) 32.8 (30.0, 36.5) 25.6 (22.3, 29.4)** 23.2 (20.8, 25.5)** 
T4 output (pmol/s) 3.90 (2.60, 7.92) – –
 *  Significant difference  < 0.05; ** Significant difference  < 0.001, Wilcoxon test, compared to untreated patients
a  For referencing purposes, thyroid parameters in disease-free individuals with a median age of 38 (26, 49) years were as follows: FT3 5.0 (4.8, 5.2) pmol/l, FT4 14.0 (13.0,15.1) 
pmol/l, TSH 1.62 (1.12, 2.25) mU/l, thyroid volume 10 (8,13) ml, deiodinase activity 32.8 (30.0, 36.2) nmol/s, and T4 output 2.88 (2.30, 3.72) pmol/s
Athyreotic patients shown here were in a compensated non-hypothyroid state on a stable L-T4 dose. For estimation of deiodinase activity and T4 output, refer to Methods
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While both deiodinases, D1 and D2, are upregulated by TSH/c-
AMP, they respond differently to T3 [4, 18, 19]. In hyperthyroid-
ism, T3 upregulates D1 and downregulates D2, whereas in 
hypothyroidism T4 deficiency mainly increases the efficiency of 
D2 [4]. A marked increase in the T3 to T4 ratio is clinically evi-
dent in both T3-dominant hyperthyroidism and many cases of 
overt hypothyroidism where FT4 is low, but FT3 found within 
the reference range. In addition to the regulation by cAMP/TSH 
and influence of thyroid state, we found that deiodinase activity 
was associated with thyroid volume, as detailed below, intro-
ducing a higher level of complexity and enabling differentiated 
control.
We conclude that the TSH effect takes place predominantly in 
the thyroid gland. Although certain peripheral tissues such as 
skeletal muscle or brown adipose tissue express both a func-
tional TSH receptor and deiodinases our results suggest that 
they may play only a minor role for systemic T3 generation, 
compared to thyroid [26, 27].
As a limitation of the study, some comparisons were made using 
thyroid volumes of patients spread over various etiological diag-
noses, such as thyroid carcinoma, autoimmune thyroiditis or 
uni- and multi-nodular goitre. However, we have previously 
shown that a TSH-FT3 disjoint exists in L-T4-treated patients 
even when stratifying by defined TSH categories and disease 
entities, comparing treated with untreated patients with auto-
immune thyroiditis or athyreotic carcinomas with normal con-
trols [10]. We calculated the sum activity of peripheral 
deiodinases, but were unable to discriminate activities by type 
of deiodinase, as the source of T3 could not be traced back. It has, 
however, been shown that the activities of D1 and D2, though 
they may respond differently to T3 and T4, are both cAMP-
dependent and generally correlated [4, 18, 19, 28]. Only indi-
rectly therefore can we infer, from a drop in FT3 levels in 
athyreotic patients, and lack of TSH response, that the thyroid 
gland itself is a major player in T3 homeostasis. The loss of the 
thyroid-derived T3 pool remained relatively uncompensated in 
L-T4-treated patients. Any bias from the low T3 syndrome 
appears negligible, because the thyroid patients were otherwise 
healthy and none of the included subjects suffered from severe 
comorbidity. For the same reason, we would not envisage any 
issues with FT3 measurements [29]. FT4, but not FT3, was 
affected by a minor bias due to variable sampling intervals from 
T4 ingestion [10]. TSH levels after L-T4 withdrawal of some car-
cinoma patients were not in full equilibrium, but this, while 
affecting central equilibria, should not prevent a response of 
peripheral deiodinases. Our prospective observational study 
permitted analysis of L-T4-treatment in a large sample, as this is 
the generally recommended mode of therapy, but patients on 
T3/T4 combinations were too few for a meaningful comparison 
and excluded from analysis. The study’s non-randomised design, 
while introducing some uncontrolled variables, permitted the 
analysis of a broad functional spectrum.
Fig. 1 Relationships between FT3 a, FT4 b, and 
deiodinase activity c and TSH in untreated subjects 
(n = 1 126) and comparison of the mean standard-
ised relationships among all thyroid parameters 
d. A blue line represents the fitted curve by locally 
weighted smooth regression and the shaded area 
the 95 % confidence interval surrounding the curve 
a–c. In panel d, the green middle line indicates 
lnTSH vs. FT3, blue lower line FT4, and orange up-
per line deiodinase activity. (Color figure available 
online only).
Fig. 2 Relationship between serum FT3 and 
glandular T4 output, as observed in 982 untreated 
patients a, and theoretically expected with no 
TSH-deiodinase interaction b. See Methods for 
the calculation of T4 output (GT) and theoretical 
modelling. The difference between the right panel 
and the left panel illustrates the T3-stabilising 
influence of the proposed additional TSH control 
over deiodinase activity. (Color figure available 
online only).
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We found important homeostatic physiological mechanisms to 
be compromised in L-T4-treated patients. Patients, with a mostly 
post-interventional low residual thyroid volume ( < 5 ml, defined 
as a cut-off associated with a decline in deiodinase activity in a 
previous study [10]), 1) have significantly reduced deiodinase 
activity and lower FT3 levels, compared to either patients with a 
higher residual capacity or untreated subjects, 2) show relatively 
reduced deiodinase activities and FT3 concentrations based on 
their serum TSH levels (TSH-FT3 disjoint), 3) lack the ability to 
raise their deiodinase activity appropriately upon TSH stimula-
tion, and 4) in contrast to L-T4-treated patients with larger vol-
umes, who responded to TSH, are unable to fine-tune their FT3 
levels in the subclinically hypothyroid state. They still respond to 
T4 deficiency by raising their deiodinase activities in the overtly 
hypothyroid state in order to partly restore FT3 levels. As might 
be expected, overt hypothyroidism was too infrequent in the 
high volume group for a conclusive comparison.
We conclude that residual thyroid capacity, deiodinase response 
to TSH and deiodinase reaction to a decline in T4 are all contrib-
uting to fine-tuning the T3 equilibria.
These findings augment our growing understanding of the com-
plexity of the thyroid pituitary regulatory processes, as 
expressed in recent publications [9, 13, 30]. It is remarkable to 
note that the interacting equilibria diverged on L-T4 treatment, 
whilst optimum healthy physiological FT3, FT4, and TSH levels 
in the circulation were not maintained [10]. Our results confirm 
earlier studies by Escobar-Morreale et al. in the rat where T4 
alone supplied by infusion, as opposed to a combination of T4 
and T3, could not simultaneously achieve normal plasma levels 
of T3, T4, and TSH, and was unable to ensure tissue euthyroidism 
[31, 32]. The studies in the rat have been questioned as to their 
relevance to human physiology by pointing out differences 
between species in deiodinase types and activities, in particular 
that the assessment of the proportion of T3 contributed by the 
human thyroid is much lower than in the rat thyroid (approx. 
20 % vs. 50 %) thereby facilitating a superior compensation in the 
absence of a thyroidal T3 pool [3, 4]. However, the maintenance 
of optimum T3 levels in various tissues on L-T4 replacement in 
athyreotic patients has never been proven in humans and the 
Fig. 3 Relationships between mean standardised FT3, FT4 or deiodi-
nase activity and TSH in L-T4-treated patients (a, n = 670), serum FT3 
and weight-adjusted daily L-T4 dose (b, n = 137, r = 0.33, p < 0.0001), 
and serum FT3 and estimated daily exogenous T4 supply (c, solid line, 
n = 137, r = 0.33, p < 0.001) in L-T4-treated athyreotic patients with thyroid 
carcinoma, compared with untreated subjects over a similar range of en-
dogenous T4 supply (c, dashed line, n = 701, r = 0.03, p = 0.45). All thyroid 
carcinoma patients were non-hypothyroid on stable L-T4 medication. T4 
supply was estimated as described in Methods. BW, body weight. In panel 
a, the green line indicates lnTSH vs. FT3, blue line FT4, and orange line 
(starting below the others and crossing over) deiodinase activity. (Color 
figure available online only).
Fig. 4 Deiodinase activity in L-T4-treated patients from 2 thyroid vol-
ume groups (cut-off 5 ml), stratified by thyroid function. The difference 
between the 2 euthyroid panels was significant. Asterices indicate signifi-
cant differences (p < 0.05), compared to euthyroid patients in each group 
(see Results for details). Euthyroid was defined by FT4 and TSH values 
within their reference limits, subclinically hypothyroid by elevated TSH 
together with an FT4 value within the reference range, and hypothyroid 
according to elevated TSH and FT4 values below the lower reference limit.
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assumption of this proportion relies on a few reports only, 
prominently a study by Pilo et al. [3, 4]. Although this study was 
well designed, participants were given high doses of iodine 
(Lugol solution), which is known to act as a blocker of thyroid 
hormone secretion and deiodination [3]. This might have led to 
an underestimation of the thyroid-derived hormone, casting 
doubt on the study’s physiological relevance. Indeed, our data 
indicate a significantly greater direct contribution of T3 from the 
thyroidal pool and, more importantly, suggest that its loss in ath-
yreotic patients may not be readily compensated owing to an 
impaired T3-homeostatic regulation. Circulatory FT3 concentra-
tions clearly varied with exogenous T4 supply, showing no sign 
of compensation or successful “autoregulation”.
The proposed overarching T3-homeostatic control may be 
regarded as an instrument of central-peripheral balance. On the 
one hand, peripheral T3 generation is influenced by TSH, as 
shown here, but on the other hand, the pituitary responds to 
both circulating FT3 and FT4 converted to T3 by D2 [1]. This 
does, however, not preclude short-term adjustments, additional 
corrections or responses to circumstantial events such as inflam-
mation at the respective tissue level, which may serve as another 
protective layer [33]. In euthyroidism, the factors involved in 
regulation are balanced, each exerting its own stabilising influ-
ence, so that the quantitative contribution by the TSH-T3 tuning 
is at its smallest in this state. However, in unbalanced situations 
the TSH-T3 cross-talk becomes increasingly important. In ath-
yreotic patients on L-T4, the physiological T3-homeostatic regu-
latory process is distorted and maintenance of adequate FT3 
concentrations becomes a function dependent on exogenous T4 
supply.
The functional consequences of the suspected TSH-deiodinase 
feed-forward motif were further elucidated by comparing clini-
cal outcomes in L-T4-treated patients with predictions of our 
theoretical model, which would suggest a stronger dependence 
of T3 generation on thyroid secretory capacity, if TSH did not 
control deiodinase activity. The model serves as an adjunct to 
the clinical data on anatomical thyroid capacity, providing esti-
mates on functional thyroid capacity. It has been validated to a 
considerable extent in previous studies, which we refer to for 
further details [11–13] (see review [11] for additional refer-
ences).
Overall, the homeostatic system seems ill-prepared for L-T4 
monotherapy, which produces an unnatural event of T4 excess 
without appropriate provision of T3, subsequently enforcing a 
situational integrating compromise (high FT4, low TSH, low 
FT3), though failing to restore T3 stability and “normality”.
Although our study has shown evidence of the break-down of 
important T3-homeostatic mechanisms we cannot answer the 
question whether the hormonal dysequilibria extend to tissues 
in L-T4-treated athyreotic patients. However, it is commonly 
assumed that a long-term equilibrium exists between plasma 
and intracellular T3 concentrations [9]. As T3 is largely created 
intracellularly and contributes to the circulating T3 pool follow-
ing its active transport across the plasma membrane, reduced T3 
levels in the circulation are likely to reflect T3 deficiency within 
the bulk of the T3-producing tissues. Experimental studies in 
the rat, discussed above, and the high dissatisfaction rate with 
the current L-T4 standard treatment patients expressed in many 
trials point in the same direction [34, 35]. Our clinical data on 
homeostatic regulation, further supported independently by 
theoretical modelling, at least cast doubt on an “autoregulated” 
and guaranteed optimum tissue supply of T3 by L-T4 treatment, 
and encourage further study of this important issue.
In summary, our results suggest that 1) the thyroid gland physi-
ologically plays a direct essential and significant part in main-
taining T3 homeostasis and fine-tuning circulating T3 
concentrations, 2) TSH is involved in coordinating central and 
peripheral mechanisms that cooperate to facilitate T3 homeo-
stasis, and 3) regulatory and capacity deficiencies together may 
contribute to an apparent inadequacy of T3-homeostatic mech-
anisms in patients on L-T4 treatment. The novel findings point to 
an intricate interactive relationship between T4–T3 conversion 
and thyroid hormone production, rather than confirming a 
divided two-step regulation and peripheral “autoregulation”.
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